

1 Efficacy and Safety of Albendazole 400 mg for 30 Days in
2 Adults Patients with Low *Loa loa* Microfilaremia: A Non-
3 Inferiority Randomized Controlled Trial Compared to
4 Ivermectin

5
6 Albendazole 400 mg for 30 days in Adult Patients with
7 Low *Loa loa* Microfilaremia

8
9 Luccheri Ndong Akomezoghe^{1,2}, Noé Patrick M'Bondoukwé^{1,2,3}, Denise Patricia Mawili Mboumba^{1,2,3}, Jacques
10 Mari Ndong Ngomo^{1,2,3}, Moutombi Ditombi Bridy Chesli^{1,2,3}, Hadry Roger Sibi Matotou^{1,3}, Valentin Migueba^{1,3},
11 Marielle Karine Bouyou Akotet^{1,2,3*}

12
13 ¹ Department of Parasitology-Myology-Tropical Medicine, Faculty of Medicine, Université des Sciences de la
14 Santé, BP 4009, Libreville - Gabon

15 ² Unité Mixte de Recherche sur les Agents Infectieux et leur Pathologie (UMRAIP), Université des Sciences de la
16 Santé, Owendo, Gabon

17 ³ Centre de REcherche biomédicale en pathogènes Infectieux et Pathologies Associées (CREIPA), Libreville,
18 Gabon

19
20 *Corresponding author

21 Email: mariellebouyou@gmail.com (MKBA)

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 **Background**

25 *Loa loa* infection is endemic in central African countries like Gabon and in West Africa. Treatment typically
26 involves the use of ivermectin and albendazole, with albendazole often used to reduce microfilaremia in
27 individuals with high microfilaremia before administering ivermectin. This study aims to evaluate the efficacy and
28 safety of albendazole in patients with low microfilaremia.

29 **Methodology and principal findings**

30 The study was conducted from November 7 to April 1 across 31 villages in the Woleu-Ntem province of northern
31 Gabon. Following a questionnaire, venous blood was collected in EDTA tubes for *Loa loa* diagnosis. Eligible
32 individuals were randomized into two treatment groups and followed for 30 days. One group received daily
33 albendazole tablets (400 mg), while the other received a single dose of ivermectin (200µg/kg). The study reported
34 a 33.0% prevalence of *Loa loa* infection in northern Gabon. In the per-protocol analysis, the mean microfilaremia
35 decreased significantly by 82.3% and 90.4% in the ALB and IVM groups, respectively ($p < 0.001$). The risk
36 difference between the treatments was 8.1% [95% CI: 16.8 ; -0.6%]. For the intention-to-treat analysis, the mean
37 microfilaremia decreased significantly by 82.4% and 90.8% in the ALB and IVM groups, respectively ($p < 0.001$),
38 with a risk difference of 8.4% [95% CI: 16.2 ; 0.6%]. Eosinophil rates decreased by day 30 in both groups, though
39 not significantly different ($p > 0.05$).

40 **Conclusions/Significance**

41 The prevalence of *Loa loa* infection (33.05%) is notably high in northern Gabon. Albendazole demonstrated
42 microfilaricidal activity in individuals with low *Loa loa* microfilaremia. However, its efficacy appears inferior to
43 that of ivermectin and seems to diminish at very low microfilarial loads.

44

45 **Author summary**

46 *Loa loa* infection is endemic in central African countries, including Gabon, and across West Africa. Despite the
47 absence of specific treatments developed for *Loa loa*, current therapeutic approaches predominantly rely on
48 diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB). Although ALB is more readily available,

49 it is typically reserved for patients with high microfilaremia due to potential severe adverse effects following
50 treatment with IVM. This study aimed to evaluate the efficacy and safety of ALB as an alternative treatment for
51 patients with low microfilaremia compared to IVM. The findings suggest that ALB could serve as a viable
52 alternative for the treatment of microfilaremic loiasis. Moreover, ALB treatment demonstrated adequate clinical
53 efficacy and safety comparable to that of IVM .

54

55

56 Introduction

57 Loiasis is a neglected filarial parasitic disease endemic to West and Central Africa [1]. It is caused by the *Loa loa*
58 worm, with adult worms residing in the skin or intermuscular fascia and microfilariae found in the blood. Over 10
59 million people are estimated to be carriers of this parasite [2]. Common clinical manifestations of loiasis include
60 Calabar swelling, eyeworm, subconjunctival migration, subcutaneous crawling, and pruritus [3,4]. There are no
61 specific drugs developed exclusively for *Loa loa*; however, current treatment strategies primarily rely on the use
62 of diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB).

63 The World Health Organization (WHO) has implemented the Community-Directed Treatment with Ivermectin
64 (CDTI) strategy to eradicate onchocerciasis and lymphatic filariasis [5,6]. However, in regions where
65 onchocerciasis coexists with loiasis, CDTI poses a risk to individuals with *Loa loa* hypermicrofilaremia, defined
66 as a parasite density higher than 8,000 microfilariae per milliliter of blood (mf/mL). Patients with this condition
67 may experience severe and/or serious adverse events (SAEs) following IVM treatment, making areas with
68 onchocerciasis-loiasis co-endemicity ineligible for CDTI [7,8]. In areas where onchocerciasis is hypoendemic,
69 such as Gabon, a Test and Treat strategy is considered an alternative [9–11]. Several studies have been conducted
70 to evaluate treatments that could safely reduce high *Loa loa* microfilaremia, thereby making populations eligible
71 for IVM treatment. Different albendazole (ALB) regimens were tested using various designs. In Cameroon,
72 administering ALB 400 mg for three days showed a reduction in microfilaremia at day 90 [12]. When patients
73 with high *Loa loa* microfilaremia were given two or six doses of ALB 800 mg every two months, a decrease in
74 microfilaremia was observed in patients receiving six doses after four months [13]. Recently in Gabon, a five-
75 week regimen of ALB 400 mg showed a reduction in microfilaremia comparable to a treatment with ALB 400 mg
76 for three weeks coupled with IVM [14]. Since the conclusion of the onchocerciasis control program activities in
77 Gabon, IVM is not readily accessible to physicians and their patients. On one hand, these studies highlight the
78 microfilaricidal effect of ALB; on the other hand, they underscore the lack of a standardized protocol for treating
79 microfilaremic loiasis.

80 A significant body of research suggests that loiasis should be regarded as a major health issue [15,16]. Most loiasis
81 patients have low microfilaremia (< 8000 mf/mL) and reside in rural areas [17,18]. In these regions, rural
82 communities primarily access ALB through local dispensaries, which are their main healthcare facilities. The local
83 populations primarily engage in agriculture, fishing and hunting, which generally do not provide substantial
84 income. Clinically, low or absent microfilaremia is often associated with frequent symptoms such as Calabar

85 swellings [4]. It would be beneficial for these populations to assess whether ALB, an inexpensive medication,
86 could be used for curative purposes in patients with low microfilaremia as an alternative to IVM.

87 Therefore, the aim of this study was to evaluate the efficacy and safety of 400 mg dose of ALB compared to IVM
88 for treating infected patients in Gabon.

89

90 **Material and methods**

91 **Study sites and population**

92 This survey was conducted among the rural populations of Woleu-Ntem, specifically in the departments of Ntem
93 and Haut Ntem. Woleu-Ntem is a province located in the northern region of Gabon, a Central African country.

94 The province has an equatorial climate characterized by hot, humid conditions and high rainfall. It is covered with
95 old secondary forests and has rich and varied wildlife [19]. In Woleu-Ntem, the overall prevalence of *Loa loa* is
96 20.2%. The rural populations live along roads and rivers, with farming being their primary activity. Fishing and
97 hunting are also common, which increases their exposure to Chrysops bites, the vectors responsible for transmitting
98 *Loa loa* [20].

99

100 **Study design**

101 This survey is a non-inferiority randomized control trial aimed at evaluating the efficacy and safety of a 400 mg
102 dose of ALB taken daily for 30 days versus a single dose of IVM at 200µg/kg. The study was conducted from
103 November 7, 2021, to April 1, 2022, in thirty-four villages within the province of Woleu-Ntem, located in northern
104 Gabon. A preliminary visit was made to inform local authorities about the study's purpose. After obtaining
105 informed consent, participants' sociodemographic and clinical data were collected. This included information on
106 the study site, participant identification, age, sex, weight, height, and clinical symptoms related to loiasis, such as
107 worm migration into the eye, Calabar swelling, adult worm migration under the skin, and pruritus.

108

109 **Inclusion criteria**

110 Eligible participants were individuals aged 18 to 75 years who were diagnosed with *Loa loa* infection confirmed
111 by microscopy, with microfilarial counts ranging from ≥ 500 to ≤ 3500 mf/mL.

112

113 **Exclusion criteria**

114 Participants were excluded if they had acute systemic illnesses, suspected allergies to benzimidazoles, or were
115 pregnant or nursing.

116

117 **Blood collection and microfilaremic loiasis diagnosis**

118 Venous blood was collected in an EDTA tube for parasitological diagnosis. A 10 μ L blood sample was examined
119 directly, and the leukoconcentration technique, as described by Ho Thi Sang and Petithory, was performed [21].

120 Microfilaremia was quantified as the number of microfilariae per milliliter of blood (mf/mL). Absence of
121 microfilaremia was defined as the absence of detectable parasites following both microscopic techniques.

122

123 **Eosinophil count**

124 Eosinophils were counted from a thin blood smear prepared from a 5 μ l sample. The count was expressed as a
125 percentage based on 100 white blood cells observed under a light microscope. A count of $\geq 7\%$ was considered
126 indicative of hypereosinophilia.

127

128 **Randomization and treatment procedure**

129 Individuals were randomly assigned to one of two treatment groups following stratification based on three levels
130 of *Loa loa* microfilaremia: 500—1500; 1501—2500; 2501—3500 mf/ml, taking into account age, gender, and the
131 level of microfilaremia. Treatment was administered as follows: patients either received a daily dose of one tablet
132 of ALB (400 mg) for 30 days or a single calculated dose of IVM (200 μ g/kg) based on the patient's weight. Both
133 treatments were supplemented with 3 mg of antihistaminic-H2 daily for 7 days. Blood samples were collected
134 before treatment initiation, and subsequently on days 2, 7, 14, and 30, to monitor microfilarial load and eosinophilia
135 throughout the follow-up period.

136

137 **Monitoring of clinical signs and adverse events**

138 Adverse events were systematically evaluated throughout the study and categorized by severity: mild if they caused
139 minimal discomfort and did not disrupt daily activities, moderate if they interfered with daily activities to a
140 noticeable extent, and severe if they significantly impaired the patient's ability to carry out normal daily tasks.

141

142 **Efficacy assessments**

143 Blood samples for direct examination (10 μ L) and leukoconcentration were collected at baseline, prior to
144 administration of the study drug, and on days 2, 7, 14, and 30 to assess microfilarial load. Given the diurnal
145 periodicity of the filarial species, all efforts were made to collect blood samples between 10:00 am and 3:00 pm.

146

147 **Monitoring of eosinophil count**

148 Eosinophils were counted from a thin blood smear using 5 μ l of blood. Blood smears were conducted at baseline,
149 prior to administration of the study drug, and on days 2, 7, 14, and 30 to assess the eosinophil levels.

150

151 **Ethical considerations**

152 This study was conducted as part of the PHYLECOG project funded by the EDCTP2 program under reference
153 TMA2019CDF-2730. The study protocol was reviewed and approved by the National Ethics Committee for
154 Scientific Research. Written informed consent was obtained from each participant after explaining the study
155 (Protocol No. 0053/2022/CNER/P/SG). The study is registered under ISRCTN14889921.

156

157 **Outcomes/Endpoints**

158 The primary endpoint of this study was the reduction rate of microfilaremia. Non-inferiority between a monthly
159 course of ALB and a single course of IVM was assessed based on the difference in reduction rates.

160 Treatment with ivermectin for microfilaremic loiasis typically results in rapid and sustained reduction, achieving
161 a reduction rate of approximately 90% after 30 days, whereas placebo generally achieves a 50% reduction [22,23].

162 To establish non-inferiority, a margin of 20% was selected using the fixed margin method, which is half the
163 difference in reduction rates observed between ivermectin and placebo.

164 The investigator monitored adverse events, categorizing them by type and severity. The primary safety endpoint
165 was the occurrence of any adverse event following treatment initiation, regardless of its relationship to the study
166 drug. The secondary safety endpoint involved tracking the evolution of eosinophil levels throughout the treatment
167 period.

168

169 **Sample size**

170 Based on an expected 73% reduction in microfilaremia with ALB and a 90% reduction with IVM [22–24], and
171 assuming a first-species risk of 5.0% and a second-species risk of 10.0%, with a non-inferiority margin of 20%, it
172 was determined that a minimum of 18 patients per group would be required for this study.

173

174 **Statistical analysis**

175 Data processing was conducted using Microsoft Excel 2016, overseen by both an operator and a checker. R
176 software version 4.3.0 was utilized for comprehensive data analysis.

177 Statistical analyses adhered to the principles outlined in the Consort 2010 statement, employing both per-protocol
178 and intention-to-treat methodologies [25]. The per-protocol analysis focused exclusively on patients who
179 completed their prescribed treatment regimen. Conversely, the intention-to-treat analysis included all randomized
180 patients, irrespective of treatment completion.

181 Categorical data such as sex, symptoms, and adverse events were summarized as absolute values and percentages.
182 These were compared using the proportion test, given the sample size was less than thirty, which is suitable for
183 such analyses.

184 Continuous variables were evaluated for normality. Variables following a normal distribution, such as age, weight,
185 height, BMI, and microfilaremia, were presented as mean \pm standard deviation. Variables not following a normal
186 distribution, like the eosinophil rate, were presented as median [1st percentile - 3rd percentile].

187 The reduction rate in microfilaremia was calculated as a percentage using the formula: ((Microfilaremia at D0 -
188 Microfilaremia during follow-up) / Microfilaremia at D0) * 100.


189 Comparisons of microfilaremia or eosinophil rate between different time points were conducted using Student's t-
190 test for normally distributed variables or the Wilcoxon signed rank test for variables with non-normal distribution.

191

192 Results

193 Patients

194 Among the 1363 registered patients, 21 were excluded, leaving 1342 participants eligible for the study. Of these,
195 406 (30.2%) presented with *Loa loa* microfilaremia. Ultimately, 48 patients were enrolled, with 24 receiving ALB
196 and 24 receiving IVM. However, during the follow-up period, 10 patients withdrew their consent (Fig 1).



197 **Fig. 1. Study flowchart.** * Refusal of venipuncture; ** Long-term traveler; **not visited**: could not be collected at
198 the appropriate times for microfilaremia assessment, but present at the following visit.

199 **Demographic and baseline characteristics**

200 The characteristics of the study population are summarized in Table 1. There were no significant differences
 201 between the two groups of patients ($p > 0.05$) in terms of sex, age, weight, height, microfilaremia, and eosinophil
 202 rate.

203 **Table 1. Descriptive characteristics of the two treatment groups at the inclusion (D0)**

	ALBENDAZOLE (n=22)	IVERMECTIN (n=24)	p-value
	n (%)	n (%)	
Male	17 (70.8)	10 (41.7)	0.08
	Mean \pm SD or median [1 st percentile - 3 rd percentile]	Mean \pm SD or median [1 st percentile - 3 rd percentile]	
Age (years)	49.8 \pm 12.5	53.0 \pm 13.6	0.4
Weight (Kg)	64.3 \pm 10.3	64.5 \pm 10.7	0.9
Height (m)	1.6 \pm 0.1	1.6 \pm 0.1	0.2
BMI (Kg/m²)	23.6 \pm 3.2	24.6 \pm 4.2	0.4
Microfilaremia (mf/mL)	1150 [700 - 1625]	1350 [875 - 2000]	0.5
Eosinophil rate (%)	16.0 [10.5 - 21.0]	16.0 [12.5 - 25.5]	0.5


204 SD: standard deviation

205

206 **Per-protocol analysis**

207 **Efficacy of treatments on the reduction of microfilaremia**

208 Both treatment groups showed significant reductions in mean microfilaremia from day 0 to day 30. Specifically,
 209 the ALB group exhibited a reduction of 82.3% (1339 to 237 mf/ml), while the IVM group showed a reduction of
 210 90.4% (1395 to 134 mf/ml) ($p < 0.001$) (Fig 2.a). The risk difference between the two treatments was 8.1% [95%
 211 CI: 16.8 ; -0.6%], and the 95% confidence interval did not exceed the margin of non-inferiority.



212

213 **Fig 2.a. Comparison of the albendazole and ivermectin parasitological cure rate (Per-protocol).** The blue
214 line on the chart represents the microfilariaemia levels of patients treated with albendazole, while the pink line
215 represents those treated with ivermectin.


216

217 **Intention-to-treat analysis and secondary outcomes**

218 **Efficacy of treatments on the reduction of microfilariaemia**

219 The mean microfilariaemia in patients from both treatment groups decreased significantly by 82.4% (1350 to 237
220 mf/ml) and 90.8% (1454 to 134 mf/ml) from day 0 to day 30 in the ALB and IVM groups, respectively ($p < 0.001$)

221 (Fig 2.b). The risk difference between the two treatments was 8.4% [95% CI: 16.5 ; 0.7%], and the 95% confidence
222 interval did not exceed the margin of non-inferiority.




223
224 **Fig 2.b. Comparison of the albendazole and ivermectin parasitological cure rate (Intention-to-treat).** In this
225 line chart, the blue line represents the microfilaraemia levels of patients treated with albendazole, while the pink
226 line represents those treated with ivermectin.
227

228 Incidence and progression of adverse events and symptoms during treatment


229 At baseline, approximately half of the patients in both groups reported symptoms: 41.7% (n=10) in the ALB group
230 and 54.2% (n=13) in the IVM group (p=0.6). The most frequent symptom was pruritus, noted in 90.0% (n=9/10)
231 of patients in the ALB group and 69.2% (n=9/13) in the IVM group. Over the course of follow-up, the number of
232 patients experiencing symptoms decreased, with no patients reporting symptoms by day 30 in either group (Fig
233 3.a).

234 In terms of adverse events, a total of 10 patients (41.7%) in the ALB group and 8 patients (33.3%) in the IVM
235 group reported adverse events by day 2 (p=0.8) (Fig 3.b). The most common adverse event in the ALB group was
236 asthenia, reported by 80.0% (n=8/10) of those experiencing adverse events, followed by increased appetite in
237 20.0% (n=2/10). In the IVM group, the most common adverse events were asthenia, reported by 50.0% (n=4/8),
238 and headache, reported by 25.0% (n=2/8) (Fig 3.b).



239
240 **Fig 3.a. Changes in clinical signs and adverse events over the 30-day follow-up period.** The histogram shows
241 adult worms in the eye with blue bars, adverse events with yellow bars, Calabar swelling with red bars, crawling
242 sensation with green bars, and pruritus with purple bars.

243




244 **Fig 3.b. Changes in clinical adverse events over the 30-day follow-up period.** The histogram shows appetite
245 disorders with pink bars, asthenia with dark gold bars, diarrhea with an aquamarine bar, headache and/or vertigo
246 with maroon bars, and nausea with a chartreuse green bar.

247

248 **Efficacy of treatments on eosinophil level reduction**

249 In both groups, eosinophil rates decreased by Day 30, although the difference was not statistically significant ($p >$
250 0.05). In the albendazole group, eosinophil rates initially increased from Day 0 to Day 2, followed by a decline
251 across subsequent visits, reducing from a median rate of 16% to 7% (Fig 8). Conversely, in the ivermectin group,
252 eosinophil rates remained stable from Day 0 to Day 14, with a decrease observed by Day 30 from a median rate
253 of 16% to 4% (Fig 4).



254 **Fig 4. Eosinophil rate progression by treatment.** The blue line on the chart depicts the eosinophil rate of patients
255 treated with albendazole, while the pink line represents those treated with ivermectin.

256

257 Discussion

258 This clinical trial represents the first comparison of a 30-day treatment regimen with ALB and IVM. The primary
259 objective was to evaluate ALB's efficacy and safety as a potential non-inferior alternative to IVM. This is
260 particularly relevant for landlocked rural populations who may have easier access to ALB than IVM.

261 In the intention-to-treat analysis of this trial, patients in both the ALB and IVM groups experienced a significant
262 decrease in mean microfilaremia from day 0 to day 30. The reduction was more pronounced among those treated
263 with IVM, with a risk difference of 8.6%. However, the 95% confidence interval for this difference did not reach
264 or exceed the non-inferiority margin of 20%. These results confirm the non-inferiority of monthly ALB treatment
265 compared to IVM.

266 For the per-protocol analysis, the same trend was observed. Patients' mean microfilaremia significantly decreased
267 from day 0 to day 30 in both the ALB and IVM groups. The reduction was more pronounced in patients treated
268 with IVM, with a risk difference of 8.1%. However, the 95% confidence interval for this risk difference did not
269 exceed the non-inferiority margin of 20%, confirming the non-inferiority of monthly ALB treatment compared to
270 IVM.

271

272 During the follow-up, the number of patients with symptoms decreased, and no patient exhibited any loiasis
273 symptoms by day 30 in either group. This highlights an adequate clinical response to both treatments. However,
274 these findings contrast with the results of the retrospective observational study by Gobbi et al., where 31.3% of
275 patients treated with a single dose of IVM and 50% of those treated with ALB (400 mg/day) were still symptomatic
276 after 30 days of treatment [26].

277 Less than half of the patients in both treatment groups experienced adverse events during the follow-up period,
278 with asthenia being the most common in both groups. The frequency of these adverse events decreased over
279 subsequent visits, indicating the treatments' safety, all of which were mild. Similar findings have been reported in
280 prior studies using comparable dosages, where no participants experienced serious adverse events [26,27].

281 Regarding the impact of both treatments on eosinophil counts, there was no statistically significant reduction
282 observed in either treatment group during the follow-up period. These results are consistent with Herrick et al.,
283 who found no decrease in eosinophil rates after two weeks of IVM treatment [28]. They also align with Klion et
284 al., who reported no reduction in eosinophil rates after 21 days of ALB treatment [24]. However, despite the lack
285 of significant decrease over the 30-day treatment period, there appeared to be a negative correlation between
286 treatment duration and eosinophil rates.

287 These findings suggest that monthly treatment with ALB could serve as a viable alternative for rural populations
288 lacking easy access to IVM and limited financial resources. The study's strengths include its randomized design,
289 prospective registration, and comprehensive analysis employing both per-protocol and intention-to-treat methods.
290 However, the study also had its limitations. Firstly, due to the nature of the treatments, blinding was not feasible.
291 Additionally, being a non-inferiority study focused on comparing microfilaremia reduction rates between
292 treatments, it had inherent constraints in assessing other potential clinical endpoints.

293

294 **Conclusion**

295 The prevalence of *Loa loa* infection is notably high in the investigated villages of the Woleu-Ntem province,
296 Gabon. While IVM treatment exhibited a more pronounced microfilaricidal effect, the difference in risk between
297 the two treatments, as indicated by the associated 95% confidence interval, did not exceed the margin of inferiority.
298 This confirms the non-inferiority of ALB treatment. Moreover, ALB treatment demonstrated an adequate clinical
299 response and exhibited good safety profiles similar to IVM.

300

301 **Acknowledgments**

302 The authors extend their sincere gratitude to all the staff at the Centre de Recherche biomédicale En pathogènes
303 Infectieux et Pathologies Associées (CREIPA) and the Unité Mixte de Recherche sur les Agents Infectieux et leur
304 Pathologie (UMRAIP) for their invaluable support in participant recruitment in Bitam, and for their assistance
305 with sample analysis in both Libreville and Bitam. Special thanks are also due to the management of the Bifolossi
306 Medical Center for generously hosting our study. We extend our appreciation to the village chiefs and other
307 relevant authorities for their unwavering support throughout this research. Finally, heartfelt thanks to all the
308 participants whose cooperation made this study possible.

309

310 **Author contributions**

311 **Conceptualization:** Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet, Noé Patrick
312 M'Bondoukwé

313 **Data curation:** Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé

314 **Formal analysis:** Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé

315 **Funding acquisition:** Marielle Karine Bouyou Akotet, Noé Patrick M'Bondoukwé

316 **Investigation:** Luccheri Ndong Akomezoghe, Mérédith Flore Ada Mengome, Roger Hadry Sibi Matotou, Bridy
317 Chesly Moutombi Ditombi, Valentin Migueba, Jacques Mari Ndong Ngomo, Noé Patrick M'Bondoukwé

318 **Methodology:** Luccheri Ndong Akomezoghe, Denise Patricia Mawili-Mboumba, Noé Patrick M'Bondoukwé

319 **Project administration:** Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet

320 **Resources:** Marielle Karine Bouyou Akotet

321 **Supervision:** Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet

322 **Validation:** Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet

323 **Visualization:** Luccheri Ndong Akomezoghe

324 **Writing-original draft:** Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé, Denise Patricia Mawili-
325 Mboumba

326 **Writing-review and editing:** Luccheri Ndong Akomezoghe, Marielle Karine Bouyou Akotet, Denise Patricia
327 Mawili-Mboumba, Noé Patrick M'Bondoukwé

328

329 **References**

- 330 1. Wanji S, Chounna Ndongmo WP, Fombad FF, Kengne-Ouafo JA, Njouendou AJ, Longang
331 Tchounkeu YF, et al. Impact of repeated annual community directed treatment with ivermectin
332 on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and
333 lymphatic filariasis elimination in areas co-endemic with *Loa loa* in Africa. *PLoS Negl Trop*
334 *Dis.* 2018;12(9):1–24.
- 335 2. Gobbi F, Buonfrate D, Boussinesq M, Chesnais CB, Pion SD, Silva R, et al. Performance of
336 two serodiagnostic tests for loiasis in a non-endemic area. *PLoS Negl Trop Dis* [Internet].
337 2020;14(5):1–11. Available from: <http://dx.doi.org/10.1371/journal.pntd.0008187>
- 338 3. Bouyou Akotet MK, Owono-Medang M, Mawili-Mboumba DP, Moussavou-Boussougou MN,
339 Nzenze Afène S, Kendjo E, et al. The relationship between microfilaraemic and
340 amicrofilaraemic loiasis involving co-infection with *Mansonella perstans* and clinical
341 symptoms in an exposed population from Gabon. *J Helminthol.* 2016;90(4):469–75.
- 342 4. Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M,
343 Kombila M. Influence of *Mansonella perstans* microfilaraemia on total IgE levels in Gabonese
344 patients co-infected with *Loa loa*. *Acta Trop* [Internet]. 2014;131(1):11–5. Available from:
345 <http://dx.doi.org/10.1016/j.actatropica.2013.11.012>
- 346 5. Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. *Rev Esp*
347 *Quimioter.* 2016;29(6):288–95.
- 348 6. Carne B, Esterre P. Filarioses. *EMC - Mal Infect.* 2012;9(2):1–19.
- 349 7. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.
350 Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for
351 *Loa loa* infection. *Lancet.* 1997;350(9070):18–22.
- 352 8. Herrick JA, Egrand F, Ounoue R, Chinda G, Ontavon C, Opda J, et al. Posttreatment reactions
353 after single-dose diethylcarbamazine or ivermectin in subjects with *Loa Loa* infection. *Clin*

- 354 Infect Dis. 2017;64(8):1017–25.
- 355 9. Ella SN, Ogoussan K, Gass K, Hundley L, Diggle PJ, Johnson O, et al. An Integrated District
356 Mapping Strategy for Loiasis to Enable Safe Mass Treatment for Onchocerciasis in Gabon. *Am*
357 *J Trop Med Hyg.* 2022;106(2):732–9.
- 358 10. Zouré HGM, Noma M, Tekle AH, Amazigo U V., Diggle PJ, Giorgi E, et al. The geographic
359 distribution of onchocerciasis in the 20 participating countries of the African Programme for
360 Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected.
361 *Parasites and Vectors.* 2014;7(1):1–15.
- 362 11. Kamgno J, Nana-Djeunga HC, Pion SD, Chesnais CB, Klion AD, Mackenzie CD, et al.
363 Operationalization of the test and not treat strategy to accelerate the elimination of
364 onchocerciasis and lymphatic filariasis in Central Africa. *Int Health.* 2018;10(March):i49–53.
- 365 12. Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, et al. Human loiasis
366 in a Cameroonian village: A double-blind, placebo-controlled, crossover clinical trial of a
367 three-day albendazole regimen. *Am J Trop Med Hyg.* 2004;71(2):211–5.
- 368 13. Kamgno J, Nguipdop-Djomo P, Gounoue R, Téjiokem M, Kuesel AC. Effect of Two or Six
369 Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double
370 Blind, Randomized, Placebo-Controlled Trial. *PLoS Negl Trop Dis.* 2016;10(3):1–19.
- 371 14. Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu
372 DG, et al. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for
373 the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled
374 assessor blinded clinical trial. *PLoS Negl Trop Dis.* 2023;17(8):e0011584.
- 375 15. Buell KG, Whittaker C, Chesnais CB, Jewell PD, Pion SDS, Walker M, et al. Atypical Clinical
376 Manifestations of Loiasis and Their Relevance for Endemic Populations. *Open Forum Infect*
377 *Dis.* 2019;6(11):1–9.
- 378 16. Id LV, Eberhardt KA, Hergeth J, Stelzl R, Manego RZ, Mombo-ngoma G, et al. Distinct loiasis

- 379 infection states and associated clinical and hematological manifestations in patients from
380 Gabon. 2022;1–15.
- 381 17. Mogoung-Wafo AE, Nana-Djeunga HC, Domche A, Fossuo-Thotchum F, Bopda J,
382 Mbickmen-Tchana S, et al. Prevalence and intensity of Loa loa infection over twenty-three
383 years in three communities of the Mbalmayo health district (Central Cameroon). *BMC Infect*
384 *Dis.* 2019;19(1):1–7.
- 385 18. Mischlinger J, Manego RZ, Id GM ngoma, Ekoka D, Id M, Hackbarth N, et al. PLOS
386 NEGLECTED TROPICAL DISEASES Diagnostic performance of capillary and venous blood
387 samples in the detection of Loa loa and Mansonella perstans microfilaraemia using light
388 microscopy. 2021;1–12.
- 389 19. Ngoua-Meye-Misso RL, Sima-Obiang C, Ndong JDLC, Ndong-Atome GR, Ondo JP, Ovono
390 Abessolo F, et al. Medicinal plants used in management of cancer and other related diseases in
391 Woleu-Ntem province, Gabon. *Eur J Integr Med* [Internet]. 2019;29(May):100924. Available
392 from: <https://doi.org/10.1016/j.eujim.2019.05.010>
- 393 20. Akue JP, Nkoghe D, Padilla C, Moussavou G, Moukana H, Mbou RA, et al. Epidemiology of
394 Concomitant Infection Due to Loa loa and Mansonella perstans in Gabon. 2011;5(10).
- 395 21. Ho Thi Sang, Petithory J. Techniques for the Concentration of Microfilariae from the Blood.
396 *Bull la Soc Pathol Exot.* 1963;56(2):197–206.
- 397 22. Pion SD, Tchatchueng-Mbouguia JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, et al.
398 Effect of a single standard dose (150-200 µg/kg) of ivermectin on loa loa microfilaremia:
399 Systematic Review and Meta-analysis. *Open Forum Infect Dis.* 2019;6(4):1–18.
- 400 23. Kamgno J, Pion SDS, Tejiokem MC, Twum-Danso NAY, Thylefors B, Boussinesq M.
401 Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia:
402 efficacy of a low dose (~25 µg/kg) versus current standard dose (150 µg/kg). *Trans R Soc Trop*
403 *Med Hyg.* 2007;101(8):777–85.

- 404 24. Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, et al.
405 Albendazole in Human Loiasis: Results of a Double-Blind, Placebo-Controlled Trial. *J Infect*
406 *Dis.* 1993;168(1):202–6.
- 407 25. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. Reporting of Noninferiority and
408 Equivalence Randomized Trials Extension of the CONSORT 2010 Statement. 2012;
- 409 26. Gobbi F, Bottieau E, Bouchaud O, Buonfrate D, Salvador F, Rojo-Marcos G, et al. Comparison
410 of different drug regimens for the treatment of loiasis—A TropNet retrospective study. *PLoS*
411 *Negl Trop Dis.* 2018;12(11):1–11.
- 412 27. Bouchaud O, Matheron S, Loarec A, Dupouy Camet J, Bourée P, Godineau N, et al. Imported
413 loiasis in France: A retrospective analysis of 167 cases with comparison between sub-Saharan
414 and non sub-Saharan African patients. *BMC Infect Dis.* 2020;20(1):1–7.
- 415 28. Herrick JA, Metenou S, Makiya MA, Taylar-Williams CA, Law MA, Klion AD, et al.
416 Eosinophil-associated processes underlie differences in clinical presentation of loiasis between
417 temporary residents and those indigenous to loa-endemic areas. *Clin Infect Dis.* 2015;60(1):55–
418 63.
- 419